IBS-D patients interested in participating in our trial, please visit prevailibsdstudy.com.


ORP-101 is a new chemical entity designed with intent to create a large stable molecule and to confer partial μ agonist and full κ-antagonist receptor pharmacology. 

Key highlights:

  • FDA Fast Track designation for IBS-D
  • No opioid-like CNS effects
  • Safe and well tolerated in Phase 1 studies
  • Phase 2 IBS-D study nearing end of enrollment, having successfully passed two interim data analyses
  • Exploring additional indications for post-IBD IBS and pancreatic pain